Pay in 4 interest-free payments of $6.06 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Para pacientes que consideran suspender o reducir el tratamiento con agonistas GLP-1, existen varias estrategias que pueden ayudar a mantener los beneficios obtenidos, aunque la evidencia sobre su efectividad es limitada
Kashkouli, Z.Z
At this time, there is not enough scientific evidence to consider it safe for use during pregnancy or breastfeeding, so avoiding it during these stages is generally recommended
Retatrutide is a triple agonist, while Tirzepatide is a dual agonist
It remains the first-line treatment for millions of people worldwide
US$ 23.80
US$ 24.10
US$ 25.58
US$ 20.56
US$ 25.70
US$ 28.99
